Indications for ADHANSIA XR:
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. Swallow whole, or may open caps and sprinkle contents onto applesauce/yogurt (swallow immediately); do not crush, chew, or divide beads. Individualize. ≥6yrs: initially 25mg once daily in the AM. May titrate by 10–15mg at intervals of ≥5 days; max 100mg/day (adults) or 85mg/day (children). Switching from other methylphenidate products: discontinue and follow Adhansia XR titration schedule. Not interchangeable on a mg-per-mg basis.
ADHANSIA XR Contraindications:
During or within 14 days of MAOIs.
Abuse and dependence.
ADHANSIA XR Warnings/Precautions:
High potential for abuse and dependence: monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors of developing a manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Allergic reactions (tartrazine). Aspirin hypersensitivity. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
ADHANSIA XR Classification:
ADHANSIA XR Interactions:
See Contraindications. Hypertensive crisis with MAOIs (eg, selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue). Efficacy may be affected with concomitant gastric pH modulators (eg, omeprazole, esomeprazole, pantoprazole, famotidine, sodium bicarbonate): monitor and use alternative based on response. Avoid alcohol.
Insomnia, dry mouth, decreased appetite, nausea, vomiting, weight loss, upper abdominal pain, feeling jittery, irritability, dizziness; hypertension, tachycardia, priapism, peripheral vasculopathy, growth suppression, psychiatric reactions.
Register pregnant patients in the National Pregnancy Registry for Psychostimulants by calling (866) 961-2388.
Generic Drug Availability: